AcelRx Pharmaceuticals Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/30/2024)
| Balance Sheet | Total Assets | 20,395,000.00 | ROE | – |
| Balance Sheet | Total Equity | 14,105,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -100,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -17,592,000.00 | – | – |
| Cashflow | Operating Cash Flow | -17,492,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -1.29 | Div. Yield | – |
| Income | Net Income | -18,397,000.00 | P/E | – |
| Income | Shares Outstanding | 14,263,700.00 | P/B | – |
| Income | Total Revenue | 651,000.00 | P/S | – |
Ratios calculated on: –
Company Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.acelrx.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more